Home/ Stocks/ SUPN

Supernus Pharmaceuticals, Inc.

SUPN XNAS

$51.53 +0.23 (+0.44%) ▲ 15-min delayed

Open

$52.46

High

$52.59

Low

$50.35

Volume

854.6K

Market Cap

$2.99B

About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 778 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$207.71M	$-2,293,000	$-0.04
FY 2025	$718.95M	$-38,550,000	$-0.68
Q3 2025	$192.10M	$-45,117,000	$-0.80
Q2 2025	$165.45M	$22.50M	$0.40

Earnings & Analyst Ratings

Next Earnings: Mon, Aug 3, 2026

Calendar →

Related Market News

No specific coverage for SUPN yet. Check out our latest market news or earnings calendar.

Get SUPN Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Supernus Pharmaceuticals, Inc..

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.